PE20221576A1 - Moduladores de la monoacilglicerol lipasa - Google Patents

Moduladores de la monoacilglicerol lipasa

Info

Publication number
PE20221576A1
PE20221576A1 PE2022001698A PE2022001698A PE20221576A1 PE 20221576 A1 PE20221576 A1 PE 20221576A1 PE 2022001698 A PE2022001698 A PE 2022001698A PE 2022001698 A PE2022001698 A PE 2022001698A PE 20221576 A1 PE20221576 A1 PE 20221576A1
Authority
PE
Peru
Prior art keywords
azabicyclo
disorders
octan
azaspiro
carbonyl
Prior art date
Application number
PE2022001698A
Other languages
English (en)
Spanish (es)
Inventor
Cynthia B Berry
Pablo Garcia-Reynaga
Brian Ngo Laforteza
Jimmy T Liang
Michael K Ameriks
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20221576A1 publication Critical patent/PE20221576A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2022001698A 2020-02-10 2021-02-09 Moduladores de la monoacilglicerol lipasa PE20221576A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972484P 2020-02-10 2020-02-10
PCT/EP2021/053062 WO2021160602A1 (en) 2020-02-10 2021-02-09 Monoacylglycerol lipase modulators

Publications (1)

Publication Number Publication Date
PE20221576A1 true PE20221576A1 (es) 2022-10-06

Family

ID=74595268

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001698A PE20221576A1 (es) 2020-02-10 2021-02-09 Moduladores de la monoacilglicerol lipasa

Country Status (23)

Country Link
US (2) US11708359B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103557B1 (cg-RX-API-DMAC7.html)
JP (1) JP7795466B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220140581A (cg-RX-API-DMAC7.html)
CN (1) CN115066422B (cg-RX-API-DMAC7.html)
AR (1) AR121296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021220539A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015116A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169988A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002136A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011275A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220376A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000162A (cg-RX-API-DMAC7.html)
EC (1) ECSP22062460A (cg-RX-API-DMAC7.html)
ES (1) ES3065721T3 (cg-RX-API-DMAC7.html)
IL (1) IL295447A (cg-RX-API-DMAC7.html)
JO (1) JOP20220180A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009804A (cg-RX-API-DMAC7.html)
PE (1) PE20221576A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552019A1 (cg-RX-API-DMAC7.html)
TW (1) TW202140465A (cg-RX-API-DMAC7.html)
UY (1) UY39066A (cg-RX-API-DMAC7.html)
WO (1) WO2021160602A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221576A1 (es) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa
KR20220158008A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제로서의 아자스피로사이클
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CA3177058A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
EP4384165B1 (en) 2021-08-09 2025-07-09 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators for use in autism spectrum disorders
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2760450A1 (en) * 2011-09-30 2014-08-06 Janssen Pharmaceutica, N.V. Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
UY37174A (es) 2016-03-31 2017-10-31 Takeda Pharmaceuticals Co Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa
GB201613163D0 (en) * 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
AU2018338855B2 (en) 2017-09-29 2022-04-28 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN112272670B (zh) 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
PE20221576A1 (es) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa
KR20220158008A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제로서의 아자스피로사이클
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CA3177058A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aryl piperidines as monoacylglycerol lipase modulators

Also Published As

Publication number Publication date
ECSP22062460A (es) 2022-11-30
UY39066A (es) 2021-08-31
EP4103557C0 (en) 2026-02-18
IL295447A (en) 2022-10-01
CN115066422A (zh) 2022-09-16
KR20220140581A (ko) 2022-10-18
BR112022015116A2 (pt) 2022-09-27
US20230382902A1 (en) 2023-11-30
TW202140465A (zh) 2021-11-01
CN115066422B (zh) 2024-11-22
MX2022009804A (es) 2022-09-02
JOP20220180A1 (ar) 2023-01-30
US20210253565A1 (en) 2021-08-19
ES3065721T3 (en) 2026-05-07
CL2022002136A1 (es) 2023-02-03
JP7795466B2 (ja) 2026-01-07
EP4103557A1 (en) 2022-12-21
CA3169988A1 (en) 2021-08-19
AR121296A1 (es) 2022-05-04
CR20220376A (es) 2022-09-16
JP2023512729A (ja) 2023-03-28
CO2022011275A2 (es) 2022-08-30
WO2021160602A1 (en) 2021-08-19
PH12022552019A1 (en) 2023-11-29
DOP2022000162A (es) 2022-10-31
EP4103557B1 (en) 2026-02-18
US11708359B2 (en) 2023-07-25
AU2021220539A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
PE20000337A1 (es) Pirazolpirimidinas y pirazoltriazinas
ECSP22062460A (es) Moduladores de la monoacilglicerol lipasa
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
KR880002808A (ko) 5-아미노-4-하이드록시 발레르산 유도체의 제조 방법
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
CR20210153A (es) Moduladores de monoacilglicerol lipasa
MX2022011901A (es) Arilo piperidinas como moduladores de monoacilglicerol lipasa.
AR008577A1 (es) Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
MX2022011904A (es) Aminociclobutanos como moduladores de monoacilglicerol lipasa.
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
ES476535A1 (es) Un procedimiento para la preparacion de nuevos derivados de acidos pirrol-1-carboxilicos.
JP2024532329A5 (cg-RX-API-DMAC7.html)
PE20040579A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen
NO165343C (no) Analogifremgangsmaate til fremstilling av nye, terapeutiskaktive 3-(2-aminoetyl)indoler.
PE20061295A1 (es) Derivados de acetileno
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
CN1204316A (zh) O-氨基甲酰基-苯丙胺醇化合物、其药学上有用的盐和它们的制备方法
SE8002345L (sv) Terapeutiska medel
PE20011213A1 (es) Sales de imidazo-3-aminas e imidazo-5-aminas biciclicas n-aciladas y sus productos de adicion con acidos, procedimientos para su preparacion y medicamentos que contienen estos compuestos
MX2022011902A (es) Moduladores de la monoacilglicerol lipasa.
DE60003435D1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
PE20050433A1 (es) 6-[fenil(sustituido)]triazolopirimidinas como agentes anticancerosos
KR940002249A (ko) 치환된 아미노티에노피리딘, 이의 제조방법 및 약제로서의 이의 용도
PE122899A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos y procedimientos para su preparacion